- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Treatment-resistant chronic migraine
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1017KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 75KB)
Galcanezumab – November 2020
Galcanezumab (chronic migraine): Injection 120 mg in 1 mL pre-filled pen; Emgality®
Last updated
19 March 2021